tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ross Osborn, 120 are a BUY (92.31%), 10 are a HOLD (7.69%).
Analyst Ross Osborn, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 35.14% that have a potential upside of 44.38% achieved within 123 days.
Ross Osborn’s has documented 252 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CVRX, CVRx at 06-Nov-2025.
Analyst best performing recommendations are on NPCE (NEUROPACE).
The best stock recommendation documented was for NPCE (NEUROPACE) at 5/14/2025. The price target of $17 was fulfilled within 1 day with a profit of $1.4 (8.97%) receiving and performance score of 89.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 10-May-2023
$2
$-0.58 (-22.48%)
$1.5
1 months 11 days ago
(15-Dec-2025)
7/7 (100%)
$-0.12 (-5.66%)
12
Hold Since 07-Jan-2022
$2
$-0.58 (-22.48%)
$1.5
2 months 15 days ago
(11-Nov-2025)
11/11 (100%)
$0.14 (7.53%)
150
Buy Since 14-Dec-2023
$2
$-0.58 (-22.48%)
$1.8
2 months 16 days ago
(10-Nov-2025)
3/4 (75%)
$0.25 (14.29%)
150
Buy Since 03-Jun-2024
$3
$0.42 (16.28%)
$4
8 months 17 days ago
(09-May-2025)
1/3 (33.33%)
$1.88 (167.86%)
40
Buy Since 13-Oct-2020
$3
$0.42 (16.28%)
$3
9 months 16 days ago
(10-Apr-2025)
5/13 (38.46%)
$1.62 (117.39%)
123
Which stock is Ross Osborn is most bullish on?
Which stock is Ross Osborn is most reserved on?
What Year was the first public recommendation made by Ross Osborn?
